NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVBXXXX and the CUSIP is 63937X103. A total of 79 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q2 2015. The put-call ratio across all filers is 110.59 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $266,000 | -28.5% | 417,835 | +2.9% | 0.00% | – |
| Q3 2016 | $372,000 | +72.2% | 405,907 | -0.2% | 0.00% | – |
| Q2 2016 | $216,000 | -94.0% | 406,720 | -89.4% | 0.00% | -100.0% |
| Q1 2016 | $3,608,000 | -32.6% | 3,820,282 | -5.2% | 0.00% | 0.0% |
| Q4 2015 | $5,357,000 | -40.0% | 4,028,112 | +2.9% | 0.00% | -50.0% |
| Q3 2015 | $8,929,000 | +40.7% | 3,916,029 | -0.7% | 0.00% | 0.0% |
| Q2 2015 | $6,347,000 | -5.1% | 3,942,167 | -6.3% | 0.00% | 0.0% |
| Q1 2015 | $6,689,000 | -14.2% | 4,206,922 | +2.0% | 0.00% | 0.0% |
| Q4 2014 | $7,795,000 | +67.6% | 4,124,161 | +17.0% | 0.00% | +100.0% |
| Q3 2014 | $4,651,000 | -14.8% | 3,523,555 | -4.5% | 0.00% | -50.0% |
| Q2 2014 | $5,459,000 | -12.5% | 3,688,518 | +9.4% | 0.00% | 0.0% |
| Q1 2014 | $6,239,000 | -6.9% | 3,372,427 | +4.2% | 0.00% | 0.0% |
| Q4 2013 | $6,700,000 | -25.3% | 3,236,654 | -4.4% | 0.00% | -33.3% |
| Q3 2013 | $8,970,000 | +12.1% | 3,384,828 | +12.9% | 0.00% | 0.0% |
| Q2 2013 | $8,003,000 | – | 2,997,381 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Platinum Management (NY) LLC | 15,046,431 | $19,861,000 | 4.55% |
| COMMERZBANK AKTIENGESELLSCHAFT /FI | 6,702,002 | $8,847,000 | 0.04% |
| LifePlan Financial Group, Inc | 28,810 | $38,000 | 0.03% |
| Hudock, Inc. | 27,500 | $36,000 | 0.02% |
| NOMURA HOLDINGS INC | 4,631,059 | $6,250,000 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 491,780 | $649,000 | 0.02% |
| Stratos Wealth Partners, LTD. | 45,535 | $60,000 | 0.01% |
| LYNCH & ASSOCIATES/IN | 18,000 | $24,000 | 0.01% |
| Tower Research Capital LLC (TRC) | 71,463 | $94,000 | 0.01% |
| SII INVESTMENTS INC/WI | 63,115 | $83,000 | 0.01% |